Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Its valuation is catching up to its earnings, but it isn't there yet.

Up 58% in 6 Months, Is InMode Stock Still a Bargain Buy?

A tanking price despite soaring profits puts this stock in value territory.

1 Growth Stock Down 65.8% That's a Bargain Right Now

You gotta love it when great stocks go on sale.

Get Into This Growth Stock for 2023 and Beyond

INMD has an expanding product portfolio and operational footprint, which translates to a growing top line. It maintains a healthy balance sheet that can fund possible M&A activity as well as its current repurchase program.

InMode: Time To Bounce In Its Expansion Mode Strategy

Doximity

These fast-growing businesses have what they need to weather an economic downturn.

2 Beaten-Down Growth Stocks You Can Confidently Buy Right Now

InMode Ltd (NASDAQ:INMD) stock continues to trade well below its October 2021 peak peak of $99.27, and was today seen 0.7% higher at $33.76.

Options Traders Should Bet on an InMode Stock Rally

YOKNEAM, Israel , Nov. 1, 2022 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will present at the following investor conferences in November: 13th Annual Jefferies London Healthcare Conference Presenters: Moshe Mizrahy, Chairman and Chief Executive Officer and Adrian Myrick, VP, Europe & Middle East Format: In-person presentation and one-on-one meetings Location: London, U.K. When: Presentation scheduled for 10:20 a.m.

InMode to Present at Upcoming Investor Conferences Before the End of 2022

Why InMode Stock Ignited This Week

InMode Ltd. (NASDAQ:INMD ) Q3 2022 Results Conference Call October 27, 2022 8:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and Chief Executive Officer Michael Kreindel - Chief Technology Officer & Director Yair Malca - Chief Financial Officer Shakil Lakhani - President, North America Spero Theodorou - Chief Medical Officer Rafael Lickerman - VP of Finance Conference Call Participants Kyle Rose - Canaccord Genuity Matt Taylor - Jefferies Jeff Johnson - Baird Joseph Conway - Needham Operator Good day and welcome to the InMode Third Quarter 2022 Earnings Results Conference Call.

InMode Ltd. (INMD) Q3 2022 Earnings Call Transcript

YOKNEAM, Israel, Oct. 27, 2022 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2022.

InMode Reports Third Quarter 2022 Financial Results; Record Quarterly Revenue of $121.2 M, Represents 29% Year-Over-Year Growth

Bank of America

General Electric

GlaxoSmithKline

JPMorgan Chase & Co

El Pollo Loco

Splunk

I know that saying “This time could be different” is dangerous. But still, when it comes to U.S. stocks, I believe that this time could be different and that the long-awaited (by me, at least) bull market may have begun.

7 Quality Stocks Selling at a Discount as Q4 Kicks Off

Management loves giving shareholders pleasant surprises with financial results.

Here's Why InMode Stock Soared Today

Conference call to be held on Thursday, October 27, 2022, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 13, 2022 /PRNewswire/ -- InMode Ltd.

InMode Expects Record Third Quarter 2022 Revenue of $120.5M-$120.9M, Raising Full-Year 2022 Revenue Guidance to $445M-450M

Costco

Intuit

Down sharply from their 52-week highs, these three growth stocks could help lead the recovery.

A Bull Market Is Coming: 3 Beaten-Down Stocks to Buy Before the Recovery

DexCom

Novartis

The bear market has gone overboard with these three stocks.

3 Highly Profitable Stocks That Are Super Cheap Right Now

InMode dedicates to closing the gap between traditional laser treatment and plastic surgery through its ablative aesthetic medical device patents. InMode's unique ecosystem will benefit from the secular demand and long-term outsourced manufacturing contracts.

InMode: Aesthetic Tech Company Targeting Paradigm 2

I called InMode a buy in June before it rallied as much as 58%. We've pulled back a bunch, and I think we likely have a local bottom in place.

InMode Is On Its Launching Pad Again

YOKNEAM, Israel , Aug. 30, 2022 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer, will present at the Baird 2022 Global Healthcare Conference on Sept.

InMode to Present at the Baird 2022 Global Healthcare Conference

AbbVie

These beaten-down stocks share a favorable outlook for their aesthetic segments.

Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode?

YOKNEAM, Israel , Aug. 8, 2022 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced that senior management including Moshe Mizrahy, Chairman and Chief Executive Officer and Yair Malca, Chief Financial Officer, will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics one-on-one Conference on Tuesday, Aug. 16, 2022.

InMode to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1-on-1 Conference

The stock could go on a tear when the market turns around.

This Beaten-Down Growth Stock Has Significant Upside Potential. Time to Buy?

Investors keep getting pleasantly surprised by financial results from this medical device company.

Here's Why InMode Stock Jumped 48% in July

InMode is up more than 50% since July 1 on higher guidance for FY22 and yet another record quarter in Q2. InMode's business has never been in better shape from a fundamental analysis point of view - its growing internationally, successfully launching new products and maintaining insanely high 80%+ Gross Margins.

InMode Stock: The H2 Mega Comeback Is Here To Stay

INMD stock will likely double, given its aggressive international expansion and entrance into the medical segment. The fact that INMD continues to report stellar gross margins of over 80%, underscores its robust profitability and excellent cost management thus far.

InMode: Alpha Long-Term Growth - Playing The Insurance Game Next

Record quarterly results have investors cheering.

News for Inmode Ltd Stock (INMD)